Document Detail

Beneficial effects of the combination of amlodipine and losartan for lowering blood pressure in spontaneously hypertensive rats.
MedLine Citation:
PMID:  19387578     Owner:  NLM     Status:  MEDLINE    
A combination of antihypertensive agents can better control blood pressure and reduce the number and severity of side effects than a monotherapy. Since both CCBs (calcium channel blockers) and ARBs (angiotensin II receptor type-1 blockers) are current and effective antihypertensive drugs, this study assessed the synergistic antihypertensive effects as well as the optimal combination ratio of these two drugs. Amlodipine (3 mg/kg) or losartan (30 mg/kg) alone or a combination of each drug at a ratio 1:10 and 1:20 was administered orally to spontaneously hypertensive rats (SHR). A four-week treatment of either 3 mg/kg amlodipine or 30 mg/kg losartan alone decreased the systolic blood pressure (SBP). However, their combination significantly lowered the SBP from the 3(rd) week, and there was a positive correlation between this reduction in blood pressure and the improvement in arterial endothelium-dependent relaxation. In addition, the combination therapy (1:20) decreased both the cardiac mass and left ventricular weight to a greater extent than with either amlodipine or losartan alone. The collagen content in the cardiac tissue was also significantly lower after the 4-week combination therapy (1:10). These results suggest that the combined use of amlodipine and losartan might be more effective in treating hypertension than a monotherapy.
Seul Min Choi; Mi Jeong Seo; Kyung Koo Kang; Jeong Hoon Kim; Byoung Ok Ahn; Moohi Yoo
Related Documents :
8519038 - Characteristics of the effects of the angiotensin converting enzyme inhibitor cilazapri...
339788 - Comparison of albuterol and isoproterenol aerosols in bronchial asthma.
2968268 - Comparison of the antihypertensive effects of celiprolol and acebutolol.
8173688 - Comparison of a felodipine-metoprolol combination tablet vs each component alone as ant...
6406888 - Postural effects on gas exchange in infants.
10806988 - Comparison of electrocardiographic criteria for diagnosis of left ventricular hypertrop...
Publication Detail:
Type:  Journal Article     Date:  2009-04-23
Journal Detail:
Title:  Archives of pharmacal research     Volume:  32     ISSN:  0253-6269     ISO Abbreviation:  Arch. Pharm. Res.     Publication Date:  2009 Mar 
Date Detail:
Created Date:  2009-04-23     Completed Date:  2009-05-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8000036     Medline TA:  Arch Pharm Res     Country:  Korea (South)    
Other Details:
Languages:  eng     Pagination:  353-8     Citation Subset:  IM    
Research Center, Dong-A Pharmaceutical Company, Yongin, 446-905, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetylcholine / pharmacology
Administration, Oral
Amlodipine / administration & dosage,  pharmacology*
Angiotensin II Type 1 Receptor Blockers / administration & dosage,  pharmacology*
Antihypertensive Agents / administration & dosage,  pharmacology*
Aorta / drug effects,  physiopathology
Blood Pressure / drug effects*
Body Weight / drug effects
Calcium Channel Blockers / administration & dosage,  pharmacology*
Cardiomegaly / etiology,  prevention & control
Collagen / metabolism
Disease Models, Animal
Drug Therapy, Combination
Hypertension / complications,  drug therapy*,  physiopathology
Losartan / administration & dosage,  pharmacology*
Myocardium / metabolism
Rats, Inbred SHR
Time Factors
Vasodilation / drug effects
Vasodilator Agents / administration & dosage,  pharmacology*
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents; 0/Calcium Channel Blockers; 0/Vasodilator Agents; 114798-26-4/Losartan; 51-84-3/Acetylcholine; 88150-42-9/Amlodipine; 9007-34-5/Collagen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of Korean red ginseng extract in a steroid-induced polycystic ovary murine model.
Next Document:  Preparation of sustained release microparticles with improved initial release property.